FDA 483 - Sri Krishna Pharmaceuticals Limited - May 19, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Sri Krishna Pharmaceuticals Ltd. - Unit 2, an Indian drug manufacturer, was cited for significant deficiencies across its quality system during an FDA inspection. The observations highlight a systemic failure in thoroughly investigating discrepancies, inadequate process controls, poor equipment cleaning, facility maintenance issues, and critical lapses in document control, data integrity, and complaint handling. These issues indicate a severe lack of oversight and adherence to GMP regulations.
ID · 69fbf128-0b1e-444d-9894-808870210337